Home Cart Sign in  
Chemical Structure| 915385-81-8 Chemical Structure| 915385-81-8

Structure of ABC294640
CAS No.: 915385-81-8

Chemical Structure| 915385-81-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ABC294640 markedly alters the ratio of ceramide/S1P consistent with inhibition of SK activity in MDA-MB-231 cells.

Synonyms: Opaganib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ABC294640

CAS No. :915385-81-8
Formula : C23H25ClN2O
M.W : 380.91
SMILES Code : O=C(C12CC3(C4=CC=C(Cl)C=C4)CC(C2)CC(C3)C1)NCC5=CC=NC=C5
Synonyms :
Opaganib
MDL No. :MFCD22666355
InChI Key :CAOTVXGYTWCKQE-UHFFFAOYSA-N
Pubchem ID :15604015

Safety of ABC294640

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PC cell lines 15 mM 6 h To investigate the effect of SPHK inhibitors on ENZ resistance in cell line models. PMC8526762
RAW264.7 cells 50 µM 24 h To test the effect of SPHK2 inhibitor on human monocytes and to evaluate inflammatory cytokine levels. PMC9847446
NSCLC cell-lines (A549, H460, H1299) 20 μM 48 h ABC294640 treatment caused significant G2 phase arrest and induced apoptosis in NSCLC cells. PMC5867242

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice ALI model induced by LPS Intraperitoneal injection 20 mg/kg once after LPS administration To alleviate macrophage-evoked oxidative injury and inflammatory reaction in lung tissues. PMC9847446
Mice H460 xenograft model Intraperitoneal injection 75 mg/kg 3 days/week for 3 weeks ABC294640 treatment represses tumor growth in vivo. PMC5867242

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04502069 COVID-19|Lung Infection PHASE1|PHASE2 WITHDRAWN 2025-06-21 Shaare Zedek Medical Center, J... More >>erusalem, Israel Less <<
NCT02229981 Diffuse Large B Cell Lymphoma|... More >>Kaposi Sarcoma Less << PHASE1|PHASE2 WITHDRAWN 2025-12-19 Louisiana State University Hea... More >>lth Sciences Center, New Orleans, Louisiana, 70112, United States Less <<
NCT02757326 Multiple Myeloma PHASE1|PHASE2 TERMINATED 2025-05-19 Duke University Medical Center... More >>, Durham, North Carolina, 27705, United States Less <<
NCT02939807 Carcinoma, Hepatocellular PHASE2 WITHDRAWN 2024-01-30 Medical University of South Ca... More >>rolina, Charleston, South Carolina, 29425, United States Less <<
NCT03414489 Cholangiocarcinoma|Cholangioca... More >>rcinoma Non-resectable|Cholangiocarcinoma, Perihilar|Cholangiocarcinoma, Extrahepatic|Cholangiocarcinoma, Intrahepatic Less << AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.13mL

2.63mL

1.31mL

26.25mL

5.25mL

2.63mL

References

 

Historical Records

Categories